131 related articles for article (PubMed ID: 17965004)
1. [Targeted therapies: the question of target detection and evaluation].
Penault-Llorca F
Bull Cancer; 2007; 94(7 Suppl):F245-8. PubMed ID: 17965004
[TBL] [Abstract][Full Text] [Related]
2. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
3. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ; Pusztai L
Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
[TBL] [Abstract][Full Text] [Related]
4. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
5. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
7. [Epidermal growth factor receptor (EGF) in head-and-neck cancers].
Bourhis J; Tao YG; Zhang P; Deutsch E
Bull Cancer; 2007; 94(7 Suppl):F189-91. PubMed ID: 17964995
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Magné N; Milano G
Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618
[TBL] [Abstract][Full Text] [Related]
10. Ten years of HER2-directed therapy: still questions after all these years.
Krop IE; Winer EP
Breast Cancer Res Treat; 2009 Jan; 113(2):207-9. PubMed ID: 18463974
[No Abstract] [Full Text] [Related]
11. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
12. HER2 in solid tumors: more than 10 years under the microscope; where are we now?
Martin V; Cappuzzo F; Mazzucchelli L; Frattini M
Future Oncol; 2014 Jun; 10(8):1469-86. PubMed ID: 25052756
[TBL] [Abstract][Full Text] [Related]
13. Targeting HER1/EGFR: a molecular approach to cancer therapy.
Arteaga C
Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
[TBL] [Abstract][Full Text] [Related]
14. Biological considerations and clinical applications of new HER2-targeted agents.
Higa GM; Singh V; Abraham J
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
[TBL] [Abstract][Full Text] [Related]
15. Established and emerging concepts in epidermal growth factor receptor biology.
Grandis JR
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S22-4. PubMed ID: 17848285
[No Abstract] [Full Text] [Related]
16. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
19. HER-1, 2, and 3.
Gettinger S
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1793-6. PubMed ID: 22005533
[No Abstract] [Full Text] [Related]
20. [Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future].
Magné N; Chargari C; Conforti R; Toillon RA; Bauduceau O; Védrine L; Khayat D; Spano JP
Bull Cancer; 2010 Mar; 97(3):385-95. PubMed ID: 20167563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
